Orum Therapeutics

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD foreign exchange exposure: ±KRW 799M pre-tax impact for 10% USD/KRW move in FY2025, reduced from ±KRW 2.01B in prior year
• • Liquidity risk: financial liabilities due within 1 year KRW 15.26B in FY2025, up from KRW 4.21B in prior year

Management Discussion & Analysis

• • Revenue KRW 23.6M (-99.89% YoY from KRW 20.9B); operating loss KRW 518B (-520.96% YoY); net loss KRW 420B (-631.15%)
• • Research & development business drove results with no new tech transfer revenue; operating loss mainly due to expanded R&D expenses

Business Overview

• • TPD² (Dual-precision Targeted Protein Degradation) technology developed combining ADC and TPD mechanisms for enhanced safety and efficacy in 2025
• • ORM-6151 (BMS-986497) licensed to Bristol Myers Squibb in Oct 2023 for relapsed/refractory AML and MDS, USD 180M deal with USD 100M received

What are the latest Orum Therapeutics DART filings in 2026?

Orum Therapeutics (KRX code 475830) has filed an annual report on March 19, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Orum Therapeutics file its most recent annual report?

Orum Therapeutics filed its most recent annual report on March 19, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Orum Therapeutics's KRX stock code?

Orum Therapeutics's KRX stock code is 475830. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 475830 to look up all Orum Therapeutics disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Orum Therapeutics file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Orum Therapeutics.

Where can I find Orum Therapeutics financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Orum Therapeutics annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.